We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos and Allergan Enter Drug Discovery Collaboration
News

Galapagos and Allergan Enter Drug Discovery Collaboration

Galapagos and Allergan Enter Drug Discovery Collaboration
News

Galapagos and Allergan Enter Drug Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos and Allergan Enter Drug Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that Galapagos' service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to €1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.

BioFocus DPI's Basel (Allschwil, Switzerland) site has provided drug discovery services for Allergan since 2002. In this new collaboration, BioFocus DPI will provide assay development and high-throughput screening services for several Allergan targets. Furthermore, BioFocus DPI's computational chemists plan to work together with Allergan to select compounds from the Allergan and BioFocus DPI compound libraries for screening against these targets.

"We are pleased to sign another collaboration with Allergan," said Onno van de Stolpe, CEO of Galapagos. "They are an important customer for BioFocus DPI's biology business and having a satisfied customer coming back for more screening is gratifying."

Advertisement